Paclitaxel for malignant pleural mesothelioma: a phase II study of the EORTC Lung Cancer Cooperative Group.

The EORTC Lung Cancer Cooperative Group undertook a phase II study of paclitaxel in 25 chemotherapy-naive patients with malignant pleural mesothelioma. Paclitaxel was given intravenously at a dose of 200 mg m-2 as a 3 h infusion every 3 weeks, after standard premedication with corticosteroids and an...

Descripción completa

Detalles Bibliográficos
Autores principales: van Meerbeeck, J., Debruyne, C., van Zandwijk, N., Postmus, P. E., Pennucci, M. C., van Breukelen, F., Galdermans, D., Groen, H., Pinson, P., van Glabbeke, M., van Marck, E., Giaccone, G.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1996
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074723/
https://www.ncbi.nlm.nih.gov/pubmed/8826866
_version_ 1782138027817041920
author van Meerbeeck, J.
Debruyne, C.
van Zandwijk, N.
Postmus, P. E.
Pennucci, M. C.
van Breukelen, F.
Galdermans, D.
Groen, H.
Pinson, P.
van Glabbeke, M.
van Marck, E.
Giaccone, G.
author_facet van Meerbeeck, J.
Debruyne, C.
van Zandwijk, N.
Postmus, P. E.
Pennucci, M. C.
van Breukelen, F.
Galdermans, D.
Groen, H.
Pinson, P.
van Glabbeke, M.
van Marck, E.
Giaccone, G.
author_sort van Meerbeeck, J.
collection PubMed
description The EORTC Lung Cancer Cooperative Group undertook a phase II study of paclitaxel in 25 chemotherapy-naive patients with malignant pleural mesothelioma. Paclitaxel was given intravenously at a dose of 200 mg m-2 as a 3 h infusion every 3 weeks, after standard premedication with corticosteroids and antihistamines. This regimen was well tolerated, with < 4% of cycles resulting in severe toxicity. No major objective responses were observed and ten patients had stable disease. Median survival time was 39 weeks and the 1 year survival rate was 30%. In conclusion, paclitaxel at the dose and schedule investigated in this trial had no major activity in the treatment of malignant pleural mesothelioma.
format Text
id pubmed-2074723
institution National Center for Biotechnology Information
language English
publishDate 1996
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-20747232009-09-10 Paclitaxel for malignant pleural mesothelioma: a phase II study of the EORTC Lung Cancer Cooperative Group. van Meerbeeck, J. Debruyne, C. van Zandwijk, N. Postmus, P. E. Pennucci, M. C. van Breukelen, F. Galdermans, D. Groen, H. Pinson, P. van Glabbeke, M. van Marck, E. Giaccone, G. Br J Cancer Research Article The EORTC Lung Cancer Cooperative Group undertook a phase II study of paclitaxel in 25 chemotherapy-naive patients with malignant pleural mesothelioma. Paclitaxel was given intravenously at a dose of 200 mg m-2 as a 3 h infusion every 3 weeks, after standard premedication with corticosteroids and antihistamines. This regimen was well tolerated, with < 4% of cycles resulting in severe toxicity. No major objective responses were observed and ten patients had stable disease. Median survival time was 39 weeks and the 1 year survival rate was 30%. In conclusion, paclitaxel at the dose and schedule investigated in this trial had no major activity in the treatment of malignant pleural mesothelioma. Nature Publishing Group 1996-09 /pmc/articles/PMC2074723/ /pubmed/8826866 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
van Meerbeeck, J.
Debruyne, C.
van Zandwijk, N.
Postmus, P. E.
Pennucci, M. C.
van Breukelen, F.
Galdermans, D.
Groen, H.
Pinson, P.
van Glabbeke, M.
van Marck, E.
Giaccone, G.
Paclitaxel for malignant pleural mesothelioma: a phase II study of the EORTC Lung Cancer Cooperative Group.
title Paclitaxel for malignant pleural mesothelioma: a phase II study of the EORTC Lung Cancer Cooperative Group.
title_full Paclitaxel for malignant pleural mesothelioma: a phase II study of the EORTC Lung Cancer Cooperative Group.
title_fullStr Paclitaxel for malignant pleural mesothelioma: a phase II study of the EORTC Lung Cancer Cooperative Group.
title_full_unstemmed Paclitaxel for malignant pleural mesothelioma: a phase II study of the EORTC Lung Cancer Cooperative Group.
title_short Paclitaxel for malignant pleural mesothelioma: a phase II study of the EORTC Lung Cancer Cooperative Group.
title_sort paclitaxel for malignant pleural mesothelioma: a phase ii study of the eortc lung cancer cooperative group.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074723/
https://www.ncbi.nlm.nih.gov/pubmed/8826866
work_keys_str_mv AT vanmeerbeeckj paclitaxelformalignantpleuralmesotheliomaaphaseiistudyoftheeortclungcancercooperativegroup
AT debruynec paclitaxelformalignantpleuralmesotheliomaaphaseiistudyoftheeortclungcancercooperativegroup
AT vanzandwijkn paclitaxelformalignantpleuralmesotheliomaaphaseiistudyoftheeortclungcancercooperativegroup
AT postmuspe paclitaxelformalignantpleuralmesotheliomaaphaseiistudyoftheeortclungcancercooperativegroup
AT pennuccimc paclitaxelformalignantpleuralmesotheliomaaphaseiistudyoftheeortclungcancercooperativegroup
AT vanbreukelenf paclitaxelformalignantpleuralmesotheliomaaphaseiistudyoftheeortclungcancercooperativegroup
AT galdermansd paclitaxelformalignantpleuralmesotheliomaaphaseiistudyoftheeortclungcancercooperativegroup
AT groenh paclitaxelformalignantpleuralmesotheliomaaphaseiistudyoftheeortclungcancercooperativegroup
AT pinsonp paclitaxelformalignantpleuralmesotheliomaaphaseiistudyoftheeortclungcancercooperativegroup
AT vanglabbekem paclitaxelformalignantpleuralmesotheliomaaphaseiistudyoftheeortclungcancercooperativegroup
AT vanmarcke paclitaxelformalignantpleuralmesotheliomaaphaseiistudyoftheeortclungcancercooperativegroup
AT giacconeg paclitaxelformalignantpleuralmesotheliomaaphaseiistudyoftheeortclungcancercooperativegroup

Ejemplares similares